TELIX Pharmaceuticals Ltd (TLX) — Cash Flow Quality Index

Latest as of June 2024: 3.04x

TELIX Pharmaceuticals Ltd (TLX) has a Cash Flow Quality Index of 3.04x as of June 2024. Operating cash flow of AU$35.45 Million exceeds net income of AU$11.68 Million, indicating high earnings quality where cash backs reported profits. Explore TELIX Pharmaceuticals Ltd (TLX) cash flow conversion to assess how effectively this company generates cash.

Cash Flow Quality Index

3.04x
Operating CF / Net Income

Operating Cash Flow

AU$35.45 Million
AUD

Net Income

AU$11.68 Million
AUD

Data as of

Jun 2024
Most recent filing

TELIX Pharmaceuticals Ltd Cash Flow Quality Index (2023–2024)

Historical Cash Flow Quality Index for TELIX Pharmaceuticals Ltd across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check TELIX Pharmaceuticals Ltd (TLX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for TELIX Pharmaceuticals Ltd (2023–2024)

Year-by-year earnings quality comparison for TELIX Pharmaceuticals Ltd. For live market cap and the full company financial profile, see TELIX Pharmaceuticals Ltd (TLX) market capitalisation.

Year Quality Index Operating CF (AUD) Net Income YoY Change
2024 0.86x AU$43.03 Million AU$49.92 Million ▼ -81.2%
2023 4.58x AU$23.88 Million AU$5.21 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.